• Chimerix Announces Topline Results from Randomized COVID-19 Clinical Trial americanpharmaceuticalreview
    March 05, 2021
    Cantex Pharmaceuticals announced Chimerix, worldwide licensee of Cantex's DSTAT investigational product, has reported promising results of the first cohort of patients hospitalized with COVID-19-associated Acute Lung Injury (ALI), suggesting that ...
  • Cantex Receives FDA Fast Track Designation for CX-01 americanpharmaceuticalreview
    August 28, 2018
    Cantex announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for Cantex's lead product candidate, CX-01, for the treatment of patients over age 60 receiving induction therapy for newly diagnosed acute myeloid leukemia (A
PharmaSources Customer Service